Connect with us

Industry News

The Flowr Corporation Completes the Acquisition of Holigen

Avatar

Published

on

default_cannabis_industry_cannamaps

TORONTO, Aug. 20, 2019 (GLOBE NEWSWIRE) — The Flowr Corporation (TSXV: FLWR; OTC: FLWPF) (“Flowr” or the “Company”) is pleased to announce the completion of the acquisition of the remaining 80.2% interest in Holigen Holdings Limited (“Holigen”) by way of a share purchase agreement, as previously announced on June 24, 2019 (the “Acquisition”).
“We are excited to complete the acquisition of Holigen and thereby add operations in Portugal and Australia to our existing Canadian platform.  The combination of our extensive cannabis cultivation know-how and Holigen’s extensive pharmaceutical experience has the potential to create tremendous value.  With an expected annual capacity of 500,000 kilograms, the Aljustrel cultivation asset in Portugal should allow us to be a significant producer in the global medical cannabis and active pharmaceutical ingredient (API) markets, initially in Europe and Australia-Asia,” said Vinay Tolia, Flowr’s Chief Executive Officer. “We continue to see the cannabis market bifurcating into premium, superior quality adult use products, where legal, and a global medical opportunity that will require massive production scale and deep GMP expertise.  With the completion of this acquisition, the subsequent ramp-up of production at Aljustrel, and the continued buildout of our campus in Kelowna, Flowr is strategically positioned to service the global cannabis market from an efficient footprint.”Total consideration for the Acquisition included:Cash consideration of CAD $6,299,423.76;Issuance of 32,632,545 Series 1 Voting Convertible Redeemable Preferred shares (“Consideration Shares”) of the Company. The Consideration Shares shall convert into common shares of the Company (“Common Shares”), on a 1:1 basis, subject to the following milestones:10% of the Consideration Shares were automatically converted into Common Shares immediately after issuance on Closing;40% of the Consideration Shares will automatically convert into Common Shares six (6) months from the Closing; andThe remaining 50% of the Consideration Shares will convert into Common Shares when and if Holigen achieves certain milestones related to the lodging of product applications and achieving certain planting targets in Australia and Portugal;The purchase of certain loans up to a maximum amount of CAD $365,188.73; and Flowr has also agreed to pay the aggregate amount of €1,378,106.53 to certain of Holigen’s creditors.Except as provided by law, the holders of Consideration Shares are entitled to vote with the holders of outstanding Common Shares and in any such vote, each Consideration Share shall be entitled to a number of votes equal to the number of Common Shares into which such Consideration Share is convertible.About The Flowr CorporationFlowr, through its subsidiaries, holds cannabis production and sales licenses granted by Health Canada. With a head office in Toronto and a production facility in Kelowna, BC, Flowr builds and operates large-scale, GMP-designed cultivation facilities utilizing its own growing systems. Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation is expected to enable it to provide premium-quality cannabis that appeals to the adult-use recreational market and addresses specific patient needs in the medicinal market.For more information, visit flowr.ca. Follow Flowr on Twitter: @FlowrCanada; Facebook: Flowr Canada; Instagram: @flowrcanada; and LinkedIn: The Flowr Corporation.On behalf of The Flowr Corporation:
Vinay Tolia
CEO and Director
CONTACT INFORMATION:MEDIA:
Sean Griffin
Vice President, Communications & Public Relations
(877) 356-9726 ext. 1526
sean.griffin@flowr.ca
INVESTORS:
Thierry Elmaleh
Head of Capital Markets
(877) 356-9726 ext. 1528
thierry@flowr.ca
Forward-Looking InformationThis press release includes forward-looking information within the meaning of Canadian securities laws regarding Flowr, Holigen and their respective businesses, which may include, but are not limited to: Flowr building its global medical platform; the combination of Flowr’s extensive cultivation know-how and Holigen’s extensive pharmaceutical experience potentially creating tremendous value; the capacity of the Aljustrel site, the scale of the Aljustrel cultivation asset allowing Flowr to be a significant producer in the global medical cannabis and API market; the cannabis market bifurcating into premium, superior quality adult use market and global medical opportunity that will require massive production scale and deep GMP expertise; ramping-up production at Aljustrel and continuing to buildout the campus in Kelowna; Flowr being strategically positioned to service the global cannabis market; the conversion of Consideration Shares into Common Shares and other statements about the Acquisition and matters ancillary thereto; the business, production and products of Flowr; and Flowr’s investment in research and development along with its sense of craftsmanship and a spirit of innovation enabling it to provide premium-quality cannabis that appeals to the adult-use recreational market and address specific patient needs in the medicinal market.Often, but not always, forward-looking information can be identified by the use of words such as “potential”, “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of Flowr’s management and are based on assumptions and subject to risks and uncertainties. Although Flowr’s management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this press release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Flowr, including risks relating to Flowr being unable to build a global medical platform; the combination of Flowr’s cultivation know-how and Holigen’s pharmaceutical experience not creating value; the Aljustrel cultivation asset not allowing Flowr to be a significant producer in the global medical cannabis and API market; the cannabis market not bifurcating in the manner Flowr anticipates and/or not requiring the anticipated production scale and GMP expertise; Flowr being unable to ramp-up production at Aljustrel and/or continue the buildout of its campus in Kelowna; the Aljustrel site not producing the expected capacity described herein, which could materially impact Flowr’s financial results and the value of Holigen; Flowr being unable to service the global cannabis market; risks relating to the use of Flowr’s or Holigen’s products; risks relating to the markets in which Flowr and Holigen operate and/or distribute their respective products; possible failure to realize the anticipated benefits of the transaction described herein; risks associated with operating in the markets in which Flowr and Holigen operate; the failure to receive licenses and/or construct Flowr’s and/or Holigen’s facilities and sites, Holigen’s license and/or product applications being delayed or not completed; general economic and stock market conditions; risks and uncertainties detailed from time to time in Flowr’s filings with the Canadian Securities Administrators; the inability of Flowr’s products to appeal to the adult-use recreational market and address specific patient needs in the medicinal market; and many other factors beyond the control of Flowr.Although Flowr has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking information can be guaranteed. Except as required by applicable securities laws, forward-looking information speaks only as of the date on which it is made and Flowr undertakes no obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release. 

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/20/1904533/0/en/The-Flowr-Corporation-Completes-the-Acquisition-of-Holigen.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

500 Patients in 100 Days and Investing in Australian Companies: Compass Lifestyle Clinics Looks towards the future of Medicinal Cannabis

Avatar

Published

on

default_cannabis_industry_cannamaps

SYDNEY, Australia, Aug. 27, 2019 (GLOBE NEWSWIRE) — Today, Starbuds International (“the Company”), parent company to Compass Lifestyle clinics (“Compass”), is pleased to provide an update on its activities since launching its first medical clinic in Sydney Australia in May.
500 patients in 100 daysWithin 100 days of opening, Compass Lifestyle Clinics has seen over 500 patients and helped provide safe access to medicinal cannabis under the watch of the Therapeutic Goods Association (“TGA”). The company is now looking to expand its capacity to serve patients across Australia.Dr. Teresa Towpik wins Doctor of the YearAt the 2019 Cannabis Industry Awards for Australia, the honours of Doctor of the Year were taken home by Compass Chief Medical Officer, Dr. Teresa Towpik. The award comes as further validation for the work Dr. Towpik has done to bring cannabis into the mainstream as a medicinal cannabis advocate in addition to her tireless work both educating doctors around prescribing as well as serving patients.Investment in Australian Cannabis Grower Medigrowth AustraliaThe Company has also secured a minority investment in Australian Medicinal cannabis late stage applicant and cultivation company Medigrowth Australia. The investment further strengthens Compass’ position in the supply chain, combining patient-centric advocacy & GP education with a leading Australian medicinal cannabis grower and extractor.
             
“Our strategic partnership with Compass consolidates our commitment to patient access and advocacy. We look forward to working with the highly respected team at Compass to educate, inspire and innovate.” says Adam Guskich, Co founder of Medigrowth Australia. “Our combined resources will prove instrumental in providing access to pure, safe, trusted and affordable Australian grown pharma grade medicinal cannabis for Australian patients.”
Along with this announcement, Brianna Martyn, Co-Founder of Starbuds International, has been appointed to the Strategic Advisory Board“Australia has welcomed us with open arms”, says Dave Martyn, President of Compass. “When we did our research, we could see Australians were underserved when it came to safe access to medicinal cannabis. At the same time, from an economic standpoint, we’ve seen what an incredible job creator the cannabis sector has been in Canada. We’ve been fortunate to partner with some of the top cannabis leaders in Australia to play a part in ensuring safe patient access while also helping to grow the industry at large.”The news at a time when medical cannabis acceptance is rapidly growing. With monthly approvals increasing recent news around the removal of red tape surrounding cannabis companies, Compass is poised to expand it’s presence in Australia as it looks towards multi-clinic expansion as well as further investment opportunities.   Those interested in learning more about Compass Lifestyle Clinics can do so at https://compassclinics.com.au or in Canada at https://compasscannabis.ca.About Compass Cannabis ClinicsCompass Cannabis Clinic is a medical cannabis service provider whose core business is focused on providing educational and consultative services to those looking for access to medicinal cannabis. Compass works with a number of Licenced Producers to ensure the right product for the patient while eliminating product bias for prescribers. With several clinics operating in Canada and over 13,000 patients served, Compass has now expanded into Australia with its first clinic in Sydney. Compass Lifestyle Clinics, located in Sydney, with plans for rapid expansion. Compass also operates recreationally in Canada as Starbuds Canada.For further information contactDaniel Winer
Marketing Director
daniel.winer@compassclinics.com.au 
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of the retail cannabis industry which the Company believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While the Company is not aware of any misstatement regarding any industry or government data presented herein, the retail cannabis industry involves risks and uncertainties and is subject to change based on various factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company’s actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e52045f5-e820-43b1-9d91-9f5d3e5e9622

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907468/0/en/500-Patients-in-100-Days-and-Investing-in-Australian-Companies-Compass-Lifestyle-Clinics-Looks-towards-the-future-of-Medicinal-Cannabis.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Radient Technologies Inc. Releases First Quarter 2020 Financial Results and Provides Corporate Update

Avatar

Published

on

default_cannabis_industry_cannamaps

EDMONTON, Alberta, Aug. 27, 2019 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a global innovator in the industrial scale extraction and downstream processing of premium grade cannabis and hemp derivatives, has released its financial results for the first quarter of its fiscal year 2020, ending June 30, 2019. The financial statements and Management’s Discussion & Analysis are available under the Company’s profile at www.SEDAR.com.
Financial Highlights:Strong cash position:As at June 30th, 2019 the Company had maintained a cash position of CAD $23.5 million.Large inventory for increased future revenue generation:As part of the Company’s business model, which will allow it to benefit from advantages related to cost, scale, and yield provided by its proprietary extraction and processing platform, Radient has secured a large inventory of cannabis biomass (valued at CAD $21.7 million), which will be processed at its Edmonton I manufacturing facility into extracts for sale to Canadian Licensed Producers. This inventory is mainly the result of Radient’s purchase of CAD $19.5 million worth of dried cannabis biomass from Canadian Licensed Producers, including Aurora Cannabis Inc. (“Aurora”), which the Company initially announced on July 8, 2019.
 
Radient has secured buyers for the majority of these extracts. Revenues earned from the sale of these extracts are expected to be in excess of the value of the current total inventory of dried cannabis biomass (CAD $21.7 million), and the Company expects this will have a meaningful positive impact on its earnings reported across fiscal Q2 2020 and/or fiscal Q3 2020. Due to various supply chain factors including shipment of biomass, product analysis and delivery of final product, the Company expects the majority of this revenue will be reported in fiscal Q3 2020.
Corporate Update:Successful scale up of throughput at Edmonton I facility:Since the commencement of extraction and processing activities at its Edmonton I facility (“Edmonton I”) in March 2019, Radient has begun to significantly scale up throughput batch sizes of cannabis biomass by multiples of 5x – 10x, in line with the Company’s expectations. Edmonton I has a throughput capacity of 56,0000 kg/ year of cannabis at full capacity.Recovery and quality of cannabinoids has exceeded expectations:Radient is pleased to report results from the scale-up at Edmonton I have proven:Cannabinoid recovery (yield) from biomass is consistently above 90%, and up to 99%.Cannabis extracts have maintained product stability, including negligible cannabinoid degradation.  Hemp processing line on track for completion:Radient’s Edmonton II Facility (“Edmonton II”), dedicated to the extraction and downstream processing of CBD from hemp, is on track for completion at the end of calendar 2019. Upon completion, Edmonton II is expected to have an annual throughput capacity of 420,000 kg/ year of hemp.Expansion into Germany:Radient’s Germany facility (‘Germany”) is expected to begin initial commissioning in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter. Please refer to the subsection titled “Germany” under “Cannabis Activities” in the MD&A for further details.Expanded throughput capacity in Canada:Radient’s Edmonton III facility (“Edmonton III”), currently under construction, is expected to be commissioned in the second half of calendar 2020, scaling up to its full capacity of 280,000 kg of cannabis and 2.8 million kg/ year of hemp thereafter.
 
Upon completion of its Edmonton II, Edmonton III and Germany facilities, Radient will have a combined total annual throughput capacity of more than 600,000 kg/year of cannabis and more than 6 million kg/ year of hemp across Canada and Germany.EU GMP compliance:Radient is building both its Edmonton III and Germany facilities to be EU GMP compliant.Post-Reporting:Improved working capital via Amended Loan Facility Agreement:The Company announced the amendment of its original loan facility with Moskowitz Capital Mortgage Fund on August 26, 2019, which increased the amount of the loan from CAD $5.5 million to $8.5 million, and extended the maturity date of the loan from November 1, 2020 to November 1, 2021.Consumer product manufacturing:In anticipation of upcoming changes to the Cannabis Act, which will make the production and sale of edible cannabis, cannabis extracts and cannabis topicals legal in Canada as of October 2019, Radient has been developing a range of compounds and formulations to meet anticipated demand of its clients. In particular, Radient has been focusing on formulation development for various vaping products, edible cannabis products, cannabis extracts and cannabis topicals that its clients will be introducing into the Canadian marketplace. The Company has developed vaping liquid formulations for commercialization and is preparing its manufacturing operations for the production of vaping liquids and cartridge filling, and expects the production of vaping liquid will begin in fiscal Q3 2020. Management Commentary:“This is a key inflection point for Radient,” Denis Taschuk, President & CEO of Radient commented. “During fiscal Q1 2020 we proved our processing and manufacturing capabilities with respect to cannabis, and subsequently acquired a large inventory of cannabis biomass in order to develop white label cannabinoid derivatives for sale to Canadian LPs. We see this as a significant turning point for Radient as a revenue generating company, and we expect this will be clearly reflected in our Q2 2020 and/ or Q3 2020 financials.”  About Radient 
Radient Technologies provides industrial-scale manufacturing solutions for premium natural ingredients and products. Utilizing its patented MAP™ extraction technology, Radient delivers superior customer outcomes in terms of ingredient purity, yield, and cost, serving global market leaders in industries such as foods & beverages, nutraceuticals, pharmaceuticals, cosmetics, and personal care. Since 2016, Radient has expanded its offerings to enter the cannabinoids market, using its proprietary platform to provide premium ingredients including those that contain a broad range of cannabinoid and terpene profiles. Please visit www.radientinc.com for more information.
SOURCE: Radient Technologies Inc.Investors please contact: William (Bill) Wasson, Senior VP of Capital Markets and Investor Relations: wwasson@radientinc.comMedia/press please contact: Caitlin Cheadle, Director of Communications: ccheadle@radientinc.comForward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the growth of the Company’s business operations; the construction of the Company’s facilities; the Company’s future revenues and timing of such revenues; the Company’s future products; the Company’s ability to sell its products and attract new customers; the expected throughput capacities at its facilities as set out in the “Corporate Update” section above;  the future recovery and quality of the Company’s extracts; the Company’s ability to expand its business internationally; the Company’s ability to grow its business in the cannabis sector and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907438/0/en/Radient-Technologies-Inc-Releases-First-Quarter-2020-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Industry News

Cannabis World Congress & Business Exposition Brings Industry’s Top Conference Program to Los Angeles

Avatar

Published

on

default_cannabis_industry_cannamaps

NEW YORK, Aug. 27, 2019 (GLOBE NEWSWIRE) — via CannabisNewsWire – Leading Edge Expositions, a company specializing in B2B trade show production, is proud to announce further details of the upcoming Cannabis World Congress & Business Exposition (CWCBExpo) in Los Angeles, California. It will run from September 26 – 28, 2019, at the Los Angeles Convention Center.
The expo has garnered a number of high-powered sponsors. Their diamond sponsor, Freed, is a prominent CBD company known for promoting healthy living. Other big sponsors include Marcum LLP, an accounting group; Zuber Lawler, a global law firm; and CCELL, known for its disruptive vaping technology. These and other leading companies in the cannabis space have come together to help make CWCBExpo a highly valuable and memorable occasion.Event organizers have also ensured the conference schedule will be packed with interesting and informative speeches, workshops and networking opportunities for all guests in attendance. The keynote address, scheduled for September 26, will be given by Steve White, CEO of Harvest, Inc. He will discuss social justice in the cannabis industry.Other speeches on the agenda will cover the cannabis industry from a myriad of angles, including the medical field, business, law and growers. For those interested in business and law, there will be additional workshops detailing how to manage the blossoming cannabis industry and what laws and regulations business owners should be aware of while their businesses grow.Finally, to provide greater ROI to every guest, speaker and sponsor attending, the expo will include multiple networking events designed to foster new business relationships to capitalize on the fast-growing market. On the evenings of September 26 and 27, CWCBExpo will offer networking opportunities for guests to unwind while making useful connections. Attendees are also encouraged to get involved in the various workshops to make important connections.Demand for CWCBExpo is sure to grow even further as the event draws closer. Attendees who purchase their tickets now will benefit from discounted pricing. To register for the upcoming Cannabis World Congress & Business Expo in Los Angeles, visit: https://www.cwcbexpo.com/attend-registration-los-angeles/About Cannabis World Congress & Business Expositions (CWCBExpo)
CWCBExpos are the premier business-to-business events for the legalized cannabis industry and are held 3 times per year in the largest financial, business, and media markets—New York, Los Angeles and Boston. Connect on Twitter, Facebook, Instagram, and LinkedIn: @cwcbexpo.
General Inquiries:
Leading Edge Expositions, LLC
Paramus, New Jersey
201.580.2050 Office
Media Contact:
CannabisNewsWire (CNW) 
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
editor@CannabisNewsWire.com

Original story can be found at: http://www.globenewswire.com/news-release/2019/08/27/1907192/0/en/Cannabis-World-Congress-Business-Exposition-Brings-Industry-s-Top-Conference-Program-to-Los-Angeles.html?f=22&fvtc=5&fvtv=41223728

Continue Reading

Trending